Your browser is no longer supported. Please, upgrade your browser.
Settings
SNGX Soligenix, Inc. daily Stock Chart
SNGX [NASD]
Soligenix, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own0.40% Shs Outstand20.14M Perf Week16.18%
Market Cap63.64M Forward P/E- EPS next Y-0.50 Insider Trans64.91% Shs Float19.69M Perf Month29.51%
Income-9.60M PEG- EPS next Q-0.13 Inst Own22.30% Short Float0.65% Perf Quarter232.63%
Sales5.00M P/S12.73 EPS this Y41.90% Inst Trans-0.82% Short Ratio0.34 Perf Half Y189.91%
Book/sh0.13 P/B24.31 EPS next Y-6.40% ROA-102.20% Target Price4.75 Perf Year251.50%
Cash/sh0.33 P/C9.64 EPS next 5Y1.00% ROE-214.60% 52W Range0.65 - 3.54 Perf YTD117.93%
Dividend- P/FCF- EPS past 5Y36.40% ROI-143.80% 52W High-10.73% Beta1.13
Dividend %- Quick Ratio1.40 Sales past 5Y10.20% Gross Margin22.00% 52W Low386.15% ATR0.29
Employees14 Current Ratio1.40 Sales Q/Q-7.10% Oper. Margin- RSI (14)66.87 Volatility11.80% 11.47%
OptionableNo Debt/Eq0.00 EPS Q/Q-27.20% Profit Margin- Rel Volume1.38 Prev Close3.34
ShortableYes LT Debt/Eq0.00 EarningsMar 24 Payout- Avg Volume372.34K Price3.16
Recom2.00 SMA2012.74% SMA5053.34% SMA200160.91% Volume514,534 Change-5.39%
Jan-31-18Downgrade H.C. Wainwright Buy → Neutral $5.50 → $2.70
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Feb-20-20 08:49AM  Independent Case Study For Soligenix's CTCL Drug, SGX301, Drives Bullish Sentiment; Topline "FLASH" Trial Data Expected Q1 2020 Newsfile
Feb-18-20 06:05AM  SNGX: KOL Interview with Dr. Brian Poligone, an Investigator in P3 FLASH Study in CTCL Zacks Small Cap Research
Feb-13-20 08:05AM  The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO Benzinga
07:00AM  FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning PR Newswire
Feb-11-20 07:00AM  Soligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas PR Newswire
Feb-03-20 07:00AM  Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis PR Newswire
Jan-30-20 08:12AM  Soligenix Stock Jumps 95% YTD Ahead of Topline Data Release For SGX301; Targeting $250 Million Unmet Market Opportunity To Treat CTCL Newsfile -6.82%
07:00AM  Soligenix to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire
Jan-28-20 02:38PM  Is Soligenix (NASDAQ:SNGX) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Jan-16-20 08:42AM  Soligenix Shares Power Higher Ahead of SGX301 Phase 3 Data Release; Projected $200 Million Revenue Opportunity For CTCL Drug Newsfile +13.26%
Jan-06-20 04:40AM  SNGX: Interview with Dr. Straube Regarding the Upcoming Phase 3 CTCL Data Readout Zacks Small Cap Research +26.21%
Dec-20-19 10:52AM  How Much is Soligenix, Inc.'s (NASDAQ:SNGX) CEO Getting Paid? Simply Wall St.
Dec-18-19 07:00AM  Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program PR Newswire
Dec-13-19 04:00PM  CORRECTION FROM SOURCE: Major Milestones for Soligenix Bring 2019 to a Strong Close Newsfile
Dec-12-19 07:00AM  Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine PR Newswire
Dec-11-19 01:30PM  Major Milestones for Soligenix Bring 2019 to a Strong Close Newsfile
Dec-05-19 05:35AM  SNGX: CTCL Phase 3 Trial Fully Enrolled; Data in 1Q20 Zacks Small Cap Research
Dec-03-19 07:00AM  Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma PR Newswire +5.11%
Nov-18-19 07:00AM  Soligenix to Present at the PCG Spotlight Series Conference PR Newswire
Nov-14-19 10:11AM  If You Had Bought Soligenix (NASDAQ:SNGX) Stock Five Years Ago, You'd Be Sitting On A 94% Loss, Today Simply Wall St.
09:40AM  SNGX: Two Phase 3 Data Readouts Over the Next Two Quarters Zacks Small Cap Research
Nov-12-19 07:00AM  Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results PR Newswire -5.66%
Nov-06-19 07:00AM  Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference PR Newswire
Oct-24-19 07:00AM  Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition PR Newswire
Oct-22-19 08:48AM  Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Release Can Change the CTCL and Oral Mucositis Treatment Landscape Newsfile
Oct-03-19 08:16AM  Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer Newsfile +7.69%
07:00AM  Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada PR Newswire
Sep-16-19 07:00AM  Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning PR Newswire
Sep-11-19 07:00AM  Soligenix Appoints Jonathan Guarino as Chief Financial Officer PR Newswire
Aug-29-19 07:00AM  Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference PR Newswire -6.82%
Aug-28-19 11:30AM  SNGX: Q&A on SGX942 Phase 3 Trial Interim Analysis Zacks Small Cap Research
07:31AM  The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved Benzinga
07:30AM  SNGX: Q&A on SGX942 Phase 3 Trial Interim Analysis Zacks Small Cap Research
07:00AM  Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer PR Newswire
Aug-22-19 11:30AM  SNGX: Interim Analysis for Phase 3 Oral Mucositis Trial Imminent Zacks Small Cap Research
Aug-15-19 07:55AM  Moleculin Completes Enrollment in Early-Stage Cancer Study Zacks
07:00AM  Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications PR Newswire
Aug-13-19 07:00AM  Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results PR Newswire
Aug-01-19 10:20AM  SNGX: What to Expect from the Upcoming Interim Analysis of SGX942 Zacks Small Cap Research
Jul-31-19 07:00AM  Soligenix Announces Conference Presentations Demonstrating Formulations of Single and Multivalent Ebola Subunit Vaccines PR Newswire
Jul-29-19 09:10AM  Potential Near Term Catalyst For Soligenix Approaches; Interim Analysis For SGX942, DOM-INNATE Trial Expected In September (NasdaqCM: SNGX) ACCESSWIRE +12.26%
07:00AM  Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract PR Newswire
Jul-15-19 09:00AM  Soligenix Inc's.(NASDAQ: SNGX) Two Late-Stage Phase III Trials Can Deliver A $500 Million Catalyst ACCESSWIRE
Jul-09-19 09:40AM  SNGX: Multiple Important Catalysts on the Horizon Zacks Small Cap Research
Jul-08-19 07:00AM  Soligenix Announces Appointment of Diane L. Parks to its Board of Directors PR Newswire +10.19%
Jun-13-19 07:00AM  Soligenix to Present RiVax® Program at the 13 Annual CounterACT Network Research Symposium PR Newswire
May-28-19 07:00AM  Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents PR Newswire
May-22-19 10:00AM  SNGX: Interim Analysis for SGX942 Phase 3 Trial Expected in Sep. 2019 Zacks Small Cap Research +11.11%
May-14-19 07:00AM  Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results PR Newswire
Apr-23-19 10:20AM  SNGX: Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial Zacks Small Cap Research
07:00AM  Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials PR Newswire
Apr-18-19 07:00AM  Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer PR Newswire
Apr-15-19 07:00AM  Soligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program PR Newswire
Apr-09-19 07:00AM  Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942 PR Newswire
Apr-04-19 07:00AM  Soligenix Receives US Patent for Dusquetide Related Analogs PR Newswire
Mar-29-19 02:15PM  SNGX: Interim Analysis of SGX942 in Oral Mucositis in Third Quarter of 2019 Zacks Small Cap Research
Mar-26-19 07:00AM  Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results PR Newswire -5.10%
Mar-11-19 07:00AM  Soligenix to Present at the Boston Oncology Investor Conference 2019 PR Newswire
Feb-12-19 11:15AM  SNGX: Innate Defense Regulators Offer New Approach to Treating Infections Zacks Small Cap Research
Feb-11-19 07:00AM  Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax® PR Newswire
Feb-07-19 07:00AM  Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate PR Newswire
Jan-23-19 06:00AM  Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs PR Newswire
Dec-11-18 08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
06:00AM  Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program PR Newswire
Dec-05-18 06:00AM  Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology PR Newswire
Nov-19-18 11:45AM  SNGX: Two Phase 3 Data Readouts Over Next 12-15 Months Zacks Small Cap Research -8.18%
Nov-14-18 08:55AM  Investor Expectations to Drive Momentum within GEE Group, GigaMedia, China XD Plastics Company, Soligenix, Energy Transfer LP, and Oil-Dri Corporation Of America Discovering Underlying Factors of Influence GlobeNewswire -6.48%
Nov-12-18 06:00AM  Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland PR Newswire -5.45%
Nov-09-18 06:00AM  Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results PR Newswire
Oct-16-18 01:45PM  SNGX: Transferring Coverage; Positive Feedback from Interim Analysis gives SGX301 Phase 3 Trial 90% probability of success Zacks Small Cap Research +5.61%
Oct-15-18 01:15PM  SNGX: Q&A with Soligenix Chief Medical Officer Dr. Richard Straube Regarding the Interim Analysis for the Phase 3 Trial of SGX301 Zacks Small Cap Research -26.21%
06:00AM  Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma PR Newswire
Oct-08-18 07:30AM  The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs Benzinga -8.25%
Oct-04-18 06:00AM  Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit PR Newswire
Sep-14-18 09:45AM  SNGX: What Can We Expect from the Upcoming Interim Analysis of Phase III SGX301 for CTCL? Zacks Small Cap Research
Sep-13-18 06:00AM  NIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program PR Newswire
Sep-05-18 06:00AM  Soligenix to Present at BioCentury's 25th Annual NewsMakers in the Biotech Industry PR Newswire
Sep-04-18 06:00AM  Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine PR Newswire
Aug-29-18 06:00AM  Soligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance PR Newswire
Aug-22-18 06:00AM  Soligenix Receives US Patent for Improved Production of Synthetic Hypericin PR Newswire -6.04%
Aug-13-18 08:01AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Soligenix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Aug-08-18 06:00AM  Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results PR Newswire +5.00%
Jul-26-18 06:00AM  Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada PR Newswire
Jul-24-18 06:00AM  Soligenix Announces Appointment of Mark Pearson to its Board of Directors PR Newswire
Jul-19-18 06:00AM  Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials PR Newswire
Jul-09-18 06:00AM  Soligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation PR Newswire
Jul-06-18 01:35PM  SNGX: New Financing Boosts Balance Sheet Zacks Small Cap Research
Jul-02-18 04:15PM  Soligenix Announces Closing of $8,000,000 At The Market Public Offering PR Newswire
Jun-28-18 06:00AM  Soligenix, Inc. Prices $8,000,000 Public Offering At The Market PR Newswire -10.57%
Jun-04-18 06:00AM  Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia PR Newswire
May-25-18 04:49PM  Soligenix Incs (NASDAQ:SNGX) Shift From Loss To Profit Simply Wall St.
May-23-18 11:25AM  SNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola Vaccine Zacks Small Cap Research
May-11-18 06:00AM  Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results PR Newswire
May-07-18 06:00AM  Soligenix to Present at the NYC Oncology Investor Conference 2018 PR Newswire
Mar-22-18 06:00AM  Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning PR Newswire
Mar-15-18 06:00AM  Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results PR Newswire
Mar-13-18 06:00AM  Soligenix to Present at the 12th Annual International Partnering Conference Bio-Europe Spring PR Newswire -5.80%
Jan-25-18 07:30AM  Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials PR Newswire
Jan-04-18 07:20AM  Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis ACCESSWIRE
Jan-02-18 06:00AM  Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis PR Newswire
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology which is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases, as well as ThermoVax, which is indicated for the thermostability of aluminum adjuvanted vaccine for ricin. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZELDIS JEROME BDirectorNov 19Buy0.932,0001,85022,917Nov 19 04:19 PM
SCHABER CHRISTOPHER JChairman, CEO and PresidentNov 19Buy0.9310,77010,01653,095Nov 19 04:18 PM
Parks Diane L.DirectorSep 23Buy0.9314,94013,87014,940Sep 23 07:15 PM
ZELDIS JEROME BDirectorSep 19Buy0.944,0003,74020,917Sep 23 04:19 PM
SCHABER CHRISTOPHER JChairman, CEO and PresidentApr 22Buy0.725,0003,57742,325Apr 22 04:41 PM
ZELDIS JEROME BDirectorApr 22Buy0.7310,0007,27416,917Apr 22 04:41 PM